预约演示

更新于：2025-05-07

Krukenberg Tumor

Krukenberg瘤

更新于：2025-05-07

基本信息

别名

Cancer metastatic to ovary、Carcinoma, Krukenberg、Krukenberg Carcinoma

+ [36]

简介

Mucocellular carcinoma of the ovary, usually metastatic from the gastrointestinal tract, characterized by areas of mucoid degeneration and the presence of signet-ring-like cells. It accounts for 30%-40% of metastatic cancers to the ovaries and possibly 1%-2% of all malignant ovarian tumors. The lesions may not be discovered until the primary disease is advanced, and most patients die of their disease within a year. In some cases, a primary tumor is not found. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1685)

关联

项与 Krukenberg瘤相关的药物

Sabizabulin

靶点

Tubulin

作用机制

微管蛋白抑制剂

在研机构

Veru, Inc. [+1]

原研机构

The Ohio State University

在研适应症

新型冠状病毒感染 [+4]

非在研适应症

Krukenberg瘤 [+10]

最高研发阶段申请上市

首次获批国家/地区-

首次获批日期1800-01-20

NP-G2-044

靶点

fascin

作用机制

fascin抑制剂

在研机构

Novita Pharmaceuticals, Inc.

原研机构

Cornell University [+1]

在研适应症

食管鳞状细胞癌 [+5]

非在研适应症

结肠癌 [+9]

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期1800-01-20

Curcumin/Doxorubicin

姜黄素/多柔比星

靶点

DNA x Top II

作用机制

DNA嵌入剂 [+1]

在研机构

Immix Biopharma Australia Pty Ltd [+2]

原研机构

Immix Biopharma, Inc.

在研适应症

晚期恶性实体瘤 [+5]

非在研适应症

Krukenberg瘤 [+1]

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期1800-01-20

项与 Krukenberg瘤相关的临床试验

NCT06914687

/ Not yet recruiting临床2期IIT

Tirellizumab Combined With SOX and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: A Single-arm, Phase II Clinical Trial (Solids-03)

For peritoneal metastatic gastric/gastroesophageal junction adenocarcinoma (cT3-4NanyM1), PD-1 antibody combined with chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) can downstage tumor stage, increase the conversion resection rate, and may improve the long-term survival. Tislelizumab, an anti-PD-1 antibody, has recently been proved in the first- and second-line standard treatment for advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma.In the subgroup analysis of RATIONALE-305 trial, tislelizumab also showed good efficacy in gastric/gastroesophageal junction adenocarcinoma patients with peritoneal metastasis. Combination of tirellizumab,SOX and HIPEC for peritoneal metastatic gastric/gastroesophageal junction adenocarcinoma could be a novel therapeutic strategy to increase response rate and therapeutic efficacy. This study is a monocenter, single-arm phase 2 clinical trial to evaluate tolerability, safety and efficacy of perioperative tirellizumab in combination with SOX and HIPEC in peritoneal metastatic gastric/gastroesophageal junction adenocarcinoma.

开始日期2025-03-30

申办/合作机构

复旦大学

NCT05143970

/ Recruiting临床1期IIT

A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

CHANCES-IPC 2021-008 is First In Human, Phase I, multicenter, European study evaluating an anti-CD73, IPH5301 in advanced and/or metastatic cancer.
The trial will be conducted in two parts, Part I- Dose escalation: This part aims to identify the maximum tolerated dose (MTD) of IPH5301 agent in monotherapy and recommended phase 2 dose (RP2D) for future trials, followed by a safety expansion study part cohort.
Part II- Expansion cohort: A total of 12 HER2+ cancer patients, respectively 6 breast cancer patients and 6 gastric cancer patients, is planned to be enrolled into the next expansion cohort to select a recommended dose of IPH5301 to be administered in combination with chemotherapy and trastuzumab for evaluation in future trials with selected advanced solid tumors.

开始日期2022-01-21

申办/合作机构

Institut Jean Paoli & Irene Calmettes

[+1]

NCT05001282

/ Terminated临床1/2期

Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors

This study, ELU- FRα-1, was focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific literature, and, in the opinion of the Investigator, have no other meaningful life-prolonging therapy options available.

开始日期2021-09-13

申办/合作机构

Elucida Oncology, Inc.

100 项与 Krukenberg瘤相关的临床结果

登录后查看更多信息

100 项与 Krukenberg瘤相关的转化医学

登录后查看更多信息

0 项与 Krukenberg瘤相关的专利（医药）

登录后查看更多信息

1,096

项与 Krukenberg瘤相关的文献（医药）

2025-05-01·European Journal of Surgical Oncology

Efficacy and safety of subtotal pelvic peritonectomy for colorectal cancer patients with peritoneal metastasis confined to the pelvic cavity

Article

作者: Tang, Jinghua ; Pan, Zhizhong ; Xiao, Binyi ; Liao, Leen ; Ding, Peirong ; Jiang, Wu ; Han, Kai ; Kong, Lingheng ; Zheng, Muxu ; Sui, Qiaoqi

BACKGROUNDCytoreductive surgery has shown survival benefits for colorectal cancer (CRC) patients with peritoneal metastasis. However, the optimal extent of peritonectomy remains controversial in cases of limited peritoneal metastases. This study modified selective pelvic peritonectomy (SPP) into subtotal pelvic peritonectomy (STPP) for metastasis confined to pelvic cavity, and aimed to evaluate its feasibility, safety, and impact on survival outcomes.MATERIALS AND METHODSCRC patients with limited peritoneal metastasis confined to the pelvic cavity who underwent CC0 (no macroscopic residual cancer remained) resection were included from a prospectively collected database. Surgical complications, disease-free survival (DFS), and overall survival (OS) were analyzed.RESULTSA total of 67 patients were included (26 in the STPP group and 41 in the SPP group). Clinically, STPP was found to be feasible and without increased surgical complications or mortality rates. At a median follow-up of 33.9 months, the 3-year DFS was 65.9 % and 30.7 % in STPP and SPP groups, respectively (P= 0.002). The 3-year OS was 84.1 % and 68.5 % in STPP and SPP groups, respectively (P= 0.006). Moreover, STTP was independently associated with improved DFS (HR = 0.351, 95 % CI 0.165-0.745, P= 0.006) and OS (HR = 0.324, 95 % CI 0.116-0.902, P=0.032). Female gender was also independently associated with poor DFS (HR = 2.146, 95 % CI 1.078-4.271, P= 0.031). Among 24 female patients with remaining ovaries, 9 (37.5 %) cases developed metachronous ovarian metastasis, and of these 6 underwent a second operation.CONCLUSIONSSubtotal pelvic peritonectomy is associated with promising long-term outcomes in CRC patients with peritoneal metastasis confined to the pelvic cavity. Prophylactic bilateral oophorectomy should be strongly considered during cytoreductive surgery.

2025-04-01·Radiology Case Reports

Krukenberg tumor secondary to gallbladder adenocarcinoma: A case report

Article

作者: Ibenyahya, Abderrahmane ; Bazi, Imane ; Saalaoui, Abir ; Wakrim, Soukaina ; Bigi, Soufiane ; Chahbi, Zakaria ; Adnor, Said ; Elagouri, Hajar

Krukenberg tumour is defined by the development of metastasis in both ovaries, characterised by the presence of mucine secreting cells, hence the name carcinoma mucocellular; However, the term "Krukenberg" has often been broadly applied to any metastases to the ovaries, irrespective of the site of origin. It is uncommon representing about 1%-2% of all ovarian tumours. It is in general secondary to a gastric adenocarcinoma but other sites have been found to be responsible of krukenberg's tumour, notably large bowels adenocarcinoma, pancreas, breast cancer, lung adenocarcinoma and biliary tract cholangiocarcinoma. In this article we will report the case of a 29 years old patient presenting with metachronous krukenberg tumour and peritoneal carcinosis with a history of surgery for a gallbladder adenocarcinoma 9 month prior. This case study sheds light on this pathology, familiarizing us with its clinical and radiological picture, as well as its prognosis.

2025-04-01·Radiology Case Reports

Unexpected encounters: The surprising link between ovarian cancer and axillary lymphadenopathy

Article

作者: Guglielmi, Giuseppe ; Carpagnano, Francesca Anna ; Balbino, Marina ; Montatore, Manuela ; Masino, Federica

Ovarian tumors represent a significant health concern for women, often leading to morbidity and mortality. We present the case of a 46-year-old patient without notable personal or family history of tumors, who initially presented with bilateral axillary lymphadenopathy. Given the clinical presentation and suspicion of a Cancer of Unknown Primary (CUP) syndrome, the patient underwent imaging examination, such as ultrasound of the axilla, mammography, and breast magnetic resonance imaging. The axillary tru-cut biopsy histological examination revealed ovarian metastasis. The total body computed tomography (CT) scan and pelvic MRI confirmed the presence of a left ovarian tumor. The patient underwent surgical intervention with excision of the tumor and axillary lymph node dissection. Histological analysis confirmed the diagnosis of high-grade serous ovarian carcinoma. The patient was initiated on adjuvant chemotherapy and a long-term follow-up was scheduled. This case underscores the importance of comprehensive diagnostic evaluation in patients presenting with suspicious symptoms, such as axillary lymphadenopathy, to ensure timely and appropriate management of ovarian carcinoma and related conditions.

分析

对领域进行一次全面的分析。

或

查看完整样例数据

Eureka LS:

全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。